Hypertension is a leading cause of heart failure and other cardiovascular diseases. Its role
in the pathogenesis of heart failure with reduced ejection fraction (HFrEF) differs from that in …

Aim Existing data on the association between blood pressure levels and adverse
cardiovascular outcomes in patients with heart failure (HF) are inconsistent. The optimal …

Hypertension is a common comorbidity in patients with heart failure and most drugs that
have demonstrated to improve prognosis in this population have the potential to reduce …

Hypertension constitutes a major risk factor for heart failure with preserved ejection fraction
(HFpEF). HFpEF is a prevalent clinical syndrome with increased cardiovascular morbidity …

The efficacy and safety of blood pressure lowering in patients with heart failure with
preserved ejection fraction (HFpEF) remain unknown. We systematically searched …

Hypertension is a major contributor to the development of heart failure with preserved
ejection fraction (HFpEF). Our understanding of the epidemiology and pathophysiology of …

Methods: Source of these meta-analyses are our databases of BP-lowering RCTs vs
placebo or less-active treatment, and head-to-head comparisons of different …

Hypertension is highly prevalent worldwide and is the major risk factor for heart failure (HF).
More than half of the patients with HF in Asia suffer from hypertension. According to the 2022 …

Abstract Purpose of Review Hypertension heralds the diagnosis of heart failure (HF) with
preserved ejection fraction (HFpEF) in 75–85% of cases and shares many of its adverse …

Aims Heart failure (HF) medication may reduce blood pressure (BP). Low BP is associated
with worse outcomes but how this association is modified by HF medication has not been …